BRAF、RET/PTC在甲状腺乳头状癌中的表达以及和颈部淋巴结转移的关系

BRAF, RET/PTC Expression in Papillary Thyroid Carcinoma and the Relationship With Cervical Lymph Node Metastasis

目的探讨BRAF、RET/PTC在甲状腺乳头状癌中的表达以及颈部淋巴结转移的关系。方法选取2014年1月—2017年1月来我院治疗甲状腺乳头状癌的患者64例,利用免疫组化法(S-P)对患者切片标本中RET/PTC基因重排情况进行检测。并利用聚合酶链法对同时期选取的另64例患者DNA样本进行BRAF基因重排扩增检测,从而对扩增结果进行鉴定。结果 RET/PTC基因重排与甲状腺癌的癌症分期具有紧密联系,且患者中出现BRAF突变,发生基因突变的原因与遗传因素有关,P<0.05,差异有统计学意义。结论对患者RET/PTC基因重排情况进行检测可为甲状腺乳头状癌临床检测提供有效的参考指标,并为下一步的靶向药物选择提供依据。

Objective To investigate the expression of BRAF and RET/PTC in papillary thyroid carcinoma and the relationship between cervical lymph node metastasis and thyroid papillary carcinoma. Methods From January 2014 to January 2017, 64 patients with papillary thyroid carcinoma were selected from our hospital. The RET/PTC gene rearrangement was detected by immunohistochemistry（S-P）. Polymerase chain reaction（PCR） was used to detect BRAF gene rearrangement in DNA samples of another 64 patients in the same period, and the amplification results were identified. Results RET/PTC gene rearrangement was closely related to the cancer stage of thyroid carcinoma, and BRAF mutation occurs in the patients. The cause of gene mutation was related to genetic factors, P〈0.05, the difference was statistically significant. Conclusion The detection of RET/PTC gene rearrangement can provide an effective reference marker for the clinical detection of papillary thyroid carcinoma, and provide the basis for the next target drug selection.